Comparing Efficacy and Safety of TJO-083 in Dry Eye Diseases Patients
Status:
COMPLETED
Trial end date:
2024-07-03
Target enrollment:
Participant gender:
Summary
In patients with dry eye syndrome, the test drug(TJO-083) or the control drug is administered for 12 weeks, and the corneal staining of each group would be evaluated. The purpose of this clinical Study is to demonstrate that the test drug is not clinically inferior to the control drug.